FBLG FibroBiologics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1958777 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY11.3%
TTM EPS YoY169.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,696.9%
ROA-211.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets73.2%
Debt / equity0.00x
Current ratio1.22x
Interest coverage-71.97x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-36.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $7.41M | $4.50M | $2.37M | $1.15M |
| SG&A expense | $9.24M | $9.23M | $6.52M | $3.32M |
| Operating income | -$16.65M | -$13.74M | -$8.89M | -$4.47M |
| Interest expense | $204,000 | $20,000 | $147,000 | $654,000 |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$18.65M | -$11.16M | -$16.48M | -$5.12M |
| EBITDA | -$16.41M | -$13.58M | -$8.84M | — |
| EPS (basic) | -0.42 | -0.34 | -0.68 | -0.18 |
| EPS (diluted) | -0.42 | -0.34 | -0.68 | -0.18 |
| Weighted avg. shares (diluted) | 44.66M | 32.88M | 28.23M | 28.23M |
| Balance sheet | ||||
| Cash & equivalents | $4.89M | $13.98M | $9.16M | $2.27M |
| Receivables | — | — | — | $300,000 |
| Current assets | $6.35M | $14.23M | $9.21M | $2.62M |
| PP&E, net | $842,000 | $824,000 | $797,000 | — |
| Total assets | $9.62M | $16.45M | $11.82M | $4.82M |
| Current liabilities | $1.76M | $12.73M | $9.18M | $7.07M |
| Total liabilities | $3.46M | $13.71M | $10.57M | $8.82M |
| Shareholders' equity | $6.16M | $2.73M | $1.25M | -$4.00M |
| Cash flow statement | ||||
| Operating cash flow | -$16.39M | -$11.90M | -$6.40M | -$4.07M |
| Capital expenditure | $262,000 | $184,000 | $495,000 | — |
| Free cash flow | -$16.66M | -$12.09M | -$6.90M | — |
| Investing cash flow | -$262,000 | -$184,000 | -$495,000 | — |
| Financing cash flow | $7.57M | $16.91M | $13.79M | $5.92M |
| Depreciation & amortization | $244,000 | $157,000 | $47,000 | — |
| Stock-based compensation | $2.69M | $2.22M | $1.76M | $265,000 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.